DnB Asset Management’s IGM Biosciences IGMS Stock Holding History

DnB Asset Management’s Portfolio IGMS Stock Details IGMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-12,280	Closed	-$1.08M	–	642
2020 Q4	$1.08M	Buy	+12,280	New	+$863K	0.01%	562

Other funds holding IGMS

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

DnB Asset Management's IGMS Position: Q1 2021 in Review

DnB Asset Management sold out of IGM Biosciences (IGMS) in Q1 2021, closing a stake of 12,280 shares — an estimated $1.08M sold.

DnB Asset Management first reported a position in IGMS in Q4 2020 and held it in 1 quarter. The position peaked at $1.08M in Q4 2020. 109 funds tracked by Wall St. Rank hold IGMS as of Q1 2021.

DnB Asset Management reported no remaining IGM Biosciences position as of Q1 2021 after selling out during the quarter.
DnB Asset Management sold 12,280 IGM Biosciences shares in Q1 2021, an estimated $1.08M.
DnB Asset Management first reported a position in IGM Biosciences in Q4 2020 and held it in 1 quarter.
DnB Asset Management's IGM Biosciences position peaked at $1.08M in Q4 2020.
109 funds tracked by Wall St. Rank held IGM Biosciences as of Q1 2021.

Based on DnB Asset Management's 13F filing for Q1 2021, filed 15 Apr 2021.